Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil

Y Yamada*,1, T Hamaguchi1, M Goto1, K Muro1, Y Matsumura1, Y Shimada1, K Shirao1 and S Nagayama2

1Medical Oncology Division, National Cancer Center Hospital, S-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; 2Taiho Pharmaceutical Co., Ltd. Pharmacokinetics Research Lab, 224-2 Ebsuna, Hiiishi, Kawauchi-cho, Tokushima 771-0194, Japan

The pharmacokinetics and pharmacodynamics of oral S-1, a dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine, were compared with those of protracted venous infusion (PVI) of 5-fluorouracil (5-FU). In all, 10 patients with gastric cancer received PVI of 5-FU at a dose of 250 mg m⁻² day⁻¹ for 5 days. After a washout period of 9 days, the patients received two divided doses daily for 28 days. S-1 was administered orally at about 0900 and 1900 hours. The daily dose of S-1 in terms of tegafur was 80 mg day⁻¹ in patients with a body surface area (BSA) of < 1.25 m², 100 mg day⁻¹ in those with a BSA of 1.25 to < 1.5 m², and 120 mg day⁻¹ in those with a BSA of ≥ 1.5 m². Plasma concentrations of 5-FU and F-β-alanine (FBAL) were measured for pharmacokinetic analysis, and the plasma uracil concentration was monitored as a surrogate marker of DPD inhibition (pharmacodynamic analysis) in the same patients on days 1–5 of PVI of 5-FU and on days 1–5 of oral S-1. The area under the curve (AUC₀–₁₀ h) of 5-FU on day 5 was 728 ± 113 ng h ml⁻¹ for PVI of 5-FU and 1364 ± 374 ng h ml⁻¹ for S-1. The median 5-FU PVI:S-1 ratio of the AUC₀–₁₀ h of 5-FU was 1.9. The AUC₀–₁₀ h of FBAL on day 5 of PVI of 5-FU was 9465 ± 3225 ng h ml⁻¹, AUC₀–₁₀ h of FBAL on day 5 of S-1 treatment. The AUC₀–₁₀ h of uracil on day 5 was 252 ± 60 ng h ml⁻¹ with PVI of 5-FU and 12 582 ± 3060 ng h ml⁻¹ with S-1. The AUC₀–₁₀ h of FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI of 5-FU, clearly demonstrating the effect of DPD inhibition.

**Keywords:** dihydropyrimidine dehydrogenase; 5-FU; pharmacokinetics; S-1

Continuous protracted intravenous infusion (PVI) of 5-fluorouracil (5-FU) has a higher response rate, less frequent haematologic toxicity (mainly neutropenia), and more frequent hand–foot syndrome (HFS) than bolus injection of 5-FU in patients with metastatic colorectal cancer (The Meta-Analysis Group in Cancer, 1998). Hand–foot syndrome and stomatitis each occur in about 23% of patients given 5-FU by PVI, whereas grade 3 leukopenia develops in only 1%. Most patients who receive 5-FU by PVI have no severe toxicity; the dose-limiting toxicity (DLT) is HFS (Lokich et al, 1993; Diasio, 1998; Kuwata et al, 2000; Kato et al, 2001). The CDHP component of S-1 decreases the incorporation of 5-fluorouracil into DNA in vitro and reduces the incidence of diarrhoea. F-β-alanine (FBAL) is a main metabolite of 5-FU. F-β-alanine and fluorocitrate are thought to cause the cardiotoxic and neurotoxic effects of 5-FU by inhibiting the tricarboxylic acid cycle (Koenig and Patel, 1970; Okeda et al, 1990; Robben et al, 1993; Diasio, 1998; Kuwata et al, 2000; Kato et al, 2001). The CDHP component of S-1 inhibits DPD, the rate-limiting enzyme in the catabolic pathway of 5-FU. Consequently, the plasma FBAL concentration after oral administration of S-1 is significantly lower than that after PVI of 5-FU. However, information on plasma FBAL concentrations in patients given 5-FU remains scant (Van Kuilenberg et al, 2001).

*Correspondence: Y Yamada; E-mail: yayamada@ncc.go.jp
Received 25 November 2002; revised 3 June 2003; accepted 29 June 2003
The objectives of this study were to investigate differences in pharmacokinetics (PK) and pharmacodynamics (PD) between oral S-1 and PVI of 5-FU and to examine the DPD inhibitory activity of S-1.

MATERIALS AND METHODS

Anticancer drugs

S-1 capsules combining tegafur, CDHP, and potassium oxonate in a molar ratio of 1 : 0.4 : 1 (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) were used. Each capsule contained 20 or 25 mg of tegafur. 5-fluorouracil was obtained from Kyowa Hakko Co., Ltd. (Tokyo, Japan).

Patients

In all, 10 consecutive patients with histologically proven metastatic gastrointestinal cancer were enrolled into this pharmacokinetic study. All patients were between 20 and 75 years of age and had an Eastern Cooperative Group (ECOG) performance status of 0 – 2, adequate baseline bone marrow (WBC count 3500 \( \mu l^{-1} \) or more and platelet 100 000 \( \mu l^{-1} \) or more, hepatic (serum bilirubin level 1.5 mg \( dl^{-1} \) or less, and serum GOT and GPT 40 U \( l^{-1} \) or less), and renal (serum creatinine level 1.2 mg \( dl^{-1} \) or less) function, and a life expectancy of at least 12 weeks.

Patients were excluded if they had symptomatic brain metastasis or other serious concurrent disease. This study was approved by the institutional review board of the National Cancer Center Hospital. Written informed consent was obtained from each patient before enrolment.

Study design

All 10 patients received 5-FU by PVI at a rate of 250 mg m\(^{-2}\) day\(^{-1}\) via a peripheral vein. Infusion was carried out with the use of a battery-operated pump (STC-508, Terumo Co., Ltd., Tokyo, Japan). 5-FU was obtained from Kyowa Hakko Co., Ltd. (Tokyo, Japan).

Between April and October 2000, 10 male patients were enrolled. Patients

Blood and urine sample collection

On days 1 and 5 of S-1 treatment, blood samples were taken before administration (0900 hours in all patients). On days 2 – 4, one blood sample was obtained at 0900 hours before the start of the next 24-h cycle. During oral administration of S-1, blood samples were taken on day 1 before the first dose of the day and at 1, 2, 4, 6, and 10 h. On days 2 – 4 of S-1 treatment, blood samples were taken before administration in the morning and at 4 and 10 h. On day 5, blood samples were obtained at 0, 2, 4, and 10 h. Peripheral blood samples (6 ml per sampling time) were collected in heparinised tubes and centrifuged at 1000 g for 15 min at 4°C. The plasma was stored at −20°C until analysis. Urine was collected from 0 to 24 h after the start of drug administration on day 1 of each treatment and refrigerated during the collection period.

Assay of 5-FU, uracil, and FBAL

Analysis of 5-FU and uracil was carried out as described by Matsushima et al (1997), with minor modification. 5-Fluorouracil and uracil were extracted with ethyl acetate after washing with dichloromethane and were subjected to a reaction to induce their trimethylsilyl derivatives. 5-Fluorouracil and uracil were analysed by electron impact ionisation gas-chromatography/mass-spectrometry (GC–MS). For analysis of 5-FU by GC–MS, stable isotopes were used as internal standards. The measurable ranges of plasma or urine levels were 1 – 400 ng ml\(^{-1}\) for 5-FU and 5 – 2000 ng ml\(^{-1}\) for uracil. For analysis of FBAL, plasma was deproteinated with ethanol and washed with dichloromethane. F-\(\beta\)-alanine was treated with 2,4-dinitrofluorobenzene to derive its dinitrophenyl ester, and the reaction product was extracted with dichloromethane under acidic conditions. The reaction product was separated by high-pressure liquid chromatography (LC) with a reversed-phase column, and LC/tandem-mass spectrometry was performed with the use of negative ion-electron spray ionisation. DL-norvaline was used as an internal standard. The measurable range of plasma or urine levels was 5 – 2000 ng ml\(^{-1}\) for FBAL.

Pharmacokinetics

Maximum plasma concentrations (\( C_{\text{max}} \)) were determined from the observed highest concentration after treatment with PVI of 5-FU or oral S-1. The area under the curve (AUC) was calculated from 0 to 10 h (AUC\(_{0–10h}\)) on days 1 and 5 of each treatment according to the trapezoidal rule, using a WinNonlin program (Ver. 3.1, Pharsight Co., Mountain View, CA, USA). The same program was used to simulate plasma 5-FU concentrations during treatment with S-1. AUCs were calculated on the basis of data obtained at the following time points: 0, 1, 2, 4, 6, and 10 h for S-1 on day 1; 0, 2, 4, and 10 h for S-1 on day 5; and 0, 2, 6, and 10 h for PVI of 5-FU on days 1 and 5.

DPP activity

DPP activity was determined by a catalytic assay as described by Ikenaka et al (1979). Blood samples were collected from patients before the start of 5-FU PVI, at about 0900 hours. Peripheral blood mononuclear cells (PBMC) prepared from about 10 ml of blood were thawed and placed in 250 \( ul \) of a homogenised buffer containing 10 mM Tris-HCl, 1 mM EDTA, and 0.5 mM dihydrothreitol, pH 7.4. The PBMCs were then homogenised by sonication, and the homogenate was centrifuged at 105 000 g for 60 min (4°C). The supernatant fraction was collected as the enzyme source and was frozen and stored at −80°C until analysis.

RESULTS

Between April and October 2000, 10 male patients were enrolled. Their median age was 66 years (range, 45 – 75 years). All 10 patients had metastatic gastric carcinoma and eight had undergone gastrectomy. Two patients had previously received chemotherapy (irinotecan plus mitomycin C in 1, and cisplatin plus irinotecan in the other). The median body surface area (BSA) was 1.52 m\(^2\) (range, 1.38 – 1.85 m\(^2\)). The initial doses of S-1 were 100 mg body\(^{-1}\) day\(^{-1}\) in four patients and 120 mg body\(^{-1}\) day\(^{-1}\) in six patients. The median actual dose of S-1 in the 10 patients was 71.6 mg m\(^{-2}\) day\(^{-1}\) (range, 64.8 – 80.0 mg m\(^{-2}\) day\(^{-1}\)) (Table 1).

5-FU, uracil, and FBAL PK

The plasma concentrations of 5-FU, uracil, and FBAL after administration of PVI 5-FU and oral S-1 in the 10 patients on days 1 – 5 are shown in Figures 1 and 2. The plasma 5-FU concentration reached a steady state 2 h after the start of PVI. This steady state was maintained throughout the 5 days. During treatment with S-1, the time to the peak plasma concentration of 5-FU was 2 – 4 h. The \( C_{\text{max}} \) of 5-FU after S-1 treatment on day 1 was
lower than the $C_{\text{max}}$ of 5-FU on days 2–5 of S-1 treatment. The plasma concentration of uracil during S-1 treatment was higher than the baseline value.

The $C_{\text{max}}$ and AUC$_{0-1\text{h}}$ of 5-FU in plasma during S-1 treatment were higher than the steady-state concentration and AUC$_{0-1\text{h}}$ of 5-FU in plasma during PVI of 5-FU. On day 5, the median AUC$_{0-1\text{h}}$ and $C_{\text{max}}$ of 5-FU with S-1 were 1.9- and 2.5-fold greater than the respective values with PVI of 5-FU.

The plasma FBAL concentration during S-1 treatment was markedly lower than that during PVI of 5-FU. On day 5, the AUC$_{0-1\text{h}}$ of FBAL with PVI of 5-FU was 5.5-fold greater than that with S-1.

### DISCUSSION

This study showed that the $C_{\text{max}}$ and AUC$_{0-1\text{h}}$ of 5-FU during treatment with oral S-1, given at dose levels recommended on the basis of phase I and II trials, were about two times greater than the respective values during PVI of 5-FU. Our results suggest that the higher incidence of leukopenia and diarrhoea associated with S-1, as compared with PVI of 5-FU, may be attributed to the significantly higher $C_{\text{max}}$ and AUC of plasma 5-FU (Thyss et al., 1986; Vokes et al., 1996; Van Groeningen et al., 2000). In the phase I trial with once daily administration schedule of S-1, pharmacodynamic analysis demonstrated a correlation between grade of diarrhoea and both $C_{\text{max}}$ of 5-FU ($r=0.57$, $P<0.05$) and AUC of 5-FU ($r=0.74$, $P<0.01$) (Cohen et al., 2002).

The plasma concentration of FBAL, the main catabolite of 5-FU, was significantly lower during S-1 treatment than during PVI of

### Table 1: Pharmacokinetic parameters of 5-FU, uracil, and FBAL in 10 patients receiving PVI and S-1

|          | PVI     | S-1     | PVI     | S-1     | PVI     | S-1     |
|----------|---------|---------|---------|---------|---------|---------|
| $C_{\text{max}}$ (ng ml$^{-1}$) |         |         |         |         |         |         |
| Day 1    | 93 ± 24 | 144 ± 33| 24 ± 7  | 1626 ± 355| 858 ± 13 | 100 ± 69|
| Day 5    | 93 ± 13 | 230 ± 69| 30 ± 9  | 1559 ± 409| 1157 ± 350| 198 ± 74|
| $P$-value | <0.001  | <0.001  | <0.001  | <0.001  | <0.001  | <0.001  |
| AUC (ng hr ml$^{-1}$) |         |         |         |         |         |         |
| Day 1    | 733 ± 164| 857 ± 209 | 200 ± 6 | 9033 ± 2176 | 6267 ± 113 | 767 ± 395|
| Day 5    | 728 ± 113| 1364 ± 374| 252 ± 60 | 12582 ± 3060 | 9465 ± 3225| 1725 ± 605|
| $P$-value | 0.181   | <0.001  | <0.001  | <0.001  | <0.001  | <0.001  |

FBAL = F-ß-alanine. *Paired t-test.

**Figure 1** Plasma concentrations of 5-FU and uracil vs time after PVI of 5-FU and after oral S-1. Closed and open circles show the concentration of 5-FU and concentration of uracil, respectively. The left and right graphs show data for PVI of 5-FU and for S-1, respectively. Data are presented as means; bars, s.d.

**Figure 2** Plasma concentration of FBAL vs time after PVI of 5-FU and after oral S-1. Closed and open circles show the plasma concentration of FBAL after S-1 and PVI of 5-FU, respectively. Data are presented as means; bars, s.d.

On day 1 of PVI of 5-FU, 1.2 ± 0.7% (range, 0.3–2.3%) and 39.2 ± 11.3% (range, 15.9–52.9%) of the administered dose was excreted in urine as 5-FU and FBAL, respectively. On day 1 of treatment with oral S-1, 7.3 ± 2.2% (range, 3.9–11.0%) and 21.7 ± 6.6% (range, 13.0–35.0%) of the administered dose were excreted in urine as 5-FU and FBAL, respectively.

The mean DPD activity of PBMC was 226 pmol min$^{-1}$ mg$^{-1}$ (range, 128–492 pmol min$^{-1}$ mg$^{-1}$). There was no correlation between the DPD activity of PBMC and the plasma concentration or AUC$_{0-1\text{h}}$ of 5-FU.

**Table 1** Pharmacokinetic parameters of 5-FU, uracil, and FBAL in 10 patients receiving PVI and S-1

|          | PVI     | S-1     | PVI     | S-1     | PVI     | S-1     |
|----------|---------|---------|---------|---------|---------|---------|
| $C_{\text{max}}$ (ng ml$^{-1}$) |         |         |         |         |         |         |
| Day 1    | 93 ± 24 | 144 ± 33| 24 ± 7  | 1626 ± 355| 858 ± 13 | 100 ± 69|
| Day 5    | 93 ± 13 | 230 ± 69| 30 ± 9  | 1559 ± 409| 1157 ± 350| 198 ± 74|
| $P$-value | <0.001  | <0.001  | <0.001  | <0.001  | <0.001  | <0.001  |
| AUC (ng hr ml$^{-1}$) |         |         |         |         |         |         |
| Day 1    | 733 ± 164| 857 ± 209 | 200 ± 6 | 9033 ± 2176 | 6267 ± 113 | 767 ± 395|
| Day 5    | 728 ± 113| 1364 ± 374| 252 ± 60 | 12582 ± 3060 | 9465 ± 3225| 1725 ± 605|
| $P$-value | 0.181   | <0.001  | <0.001  | <0.001  | <0.001  | <0.001  |

FBAL = F-ß-alanine. *Paired t-test.

**Figure 1** Plasma concentrations of 5-FU and uracil vs time after PVI of 5-FU and after oral S-1. Closed and open circles show the concentration of 5-FU and concentration of uracil, respectively. The left and right graphs show data for PVI of 5-FU and for S-1, respectively. Data are presented as means; bars, s.d.

**Figure 2** Plasma concentration of FBAL vs time after PVI of 5-FU and after oral S-1. Closed and open circles show the plasma concentration of FBAL after S-1 and PVI of 5-FU, respectively. Data are presented as means; bars, s.d.

On day 1 of PVI of 5-FU, 1.2 ± 0.7% (range, 0.3–2.3%) and 39.2 ± 11.3% (range, 15.9–52.9%) of the administered dose was excreted in urine as 5-FU and FBAL, respectively. On day 1 of treatment with oral S-1, 7.3 ± 2.2% (range, 3.9–11.0%) and 21.7 ± 6.6% (range, 13.0–35.0%) of the administered dose were excreted in urine as 5-FU and FBAL, respectively.

The mean DPD activity of PBMC was 226 pmol min$^{-1}$ mg$^{-1}$ (range, 128–492 pmol min$^{-1}$ mg$^{-1}$). There was no correlation between the DPD activity of PBMC and the plasma concentration or AUC$_{0-1\text{h}}$ of 5-FU.
S-5FU. The AUC<sub>C<sub>max</sub></sub> of the plasma FBAL concentration on day 5 of PVI of S-5FU was five-fold higher than that on day 5 of treatment with S-1. The plasma uracil concentration increased during S-1 treatment. The <i>C<sub>max</sub></i> of uracil was attained 4 h after oral administration of S-1 and decreased at 10 h. These results provide evidence that CDHP reversibly inhibits DPD. Plasma levels of FBAL and uracil have also been measured in European phase I studies of S-1. Very low levels of FBAL were detected because of DPD inhibition in 4 patients given S-1 (Van Kuilenberg et al, 2001). This low level of FBAL in plasma may be responsible for the decreased incidence of neurotoxicity and cardiotoxicity associated with S-5FU. In fact, several phase I and II clinical trials of S-1 have reported no cardiotoxicity or neurotoxicity (Taguchi et al, 1997; Sakata et al, 1998; Sugimachi et al, 1999; Koizumi et al, 2000; Ohtsu et al, 2000; Cohen et al, 2002; Chollet et al, 2003; Hoff et al, 2003; Van den Brande et al, 2003).

Capicitabine is also an oral fluoropyrimidine derivative (Budman et al, 1998). When capicitabine was administered orally after meals at a dose of 1255 mg·m<sup>-2</sup>, the AUC of the plasma FBAL concentration was 31 400 ng·h·ml<sup>-1</sup> (Reigner et al, 1998). This is 3.4-fold greater than the AUC of FBAL during PVI of 5-FU and 18-fold higher than that during treatment with oral S-1. The AUC of plasma 5-FU after treatment with capicitabine was 698 ng·hr·ml<sup>-1</sup>, and the <i>C<sub>max</sub></i> of plasma 5-FU was 310 ng·ml<sup>-1</sup>. The AUC of S-5FU was similar to that during PVI of 5-FU and about half that during treatment with S-1. The <i>C<sub>max</sub></i> of 5-FU was 3.3-fold higher than that during PVI of 5-FU and 1.3-fold higher than that during S-1 treatment. Thus, the AUC of the plasma FBAL concentration after oral capicitabine was much higher than that after oral S-1. In a randomised phase II trial of capicitabine in patients with metastatic colorectal cancer, the incidence of cardiotoxicity was 5% (five out of 108) (Van Cutsem et al, 2000). The treatment was discontinued in four patients because of chest pain, angina, or atrial fibrillation. Paresthesia occurred in 12% of the patients (Van Cutsem et al, 2000). The incidence of neurotoxicity was high, as compared with that during PVI of 5-FU or during treatment with S-1.

Capicitabine is associated with a high incidence of HFS, occurring in 45% of patients (Van Cutsem et al, 2000). The incidence of grade 3 HFS is 15–18% (Van Cutsem et al, 2000, 2001; Hoff et al, 2001). Hand–foot syndrome is also a major problem during PVI of 5-FU with a reported incidence of about 23% (Lokich et al, 1989). S-1 has a very low incidence of HFS (Taguchi et al, 1997; Sakata et al, 1998; Sugimachi et al, 1999; Koizumi et al, 2000; Ohtsu et al, 2000; Van Groeningen et al, 2000; Cohen et al, 2002; Hoff et al, 2003; Peters et al, 2003). Hand–foot syndrome has been observed in just eight out of 3808 mainly Asian patients (0.2%) treated with S-1, according to the safety database of the manufacturer of this compound, Taiho Pharmaceuticals. In addition, HFS occurred in 9–10% in European phase II trial; however, most of the cases were limited to grade 1–2 (Chollet et al, 2003; Van den Brande et al, 2003). Interestingly, a low incidence of HFS has also been reported for eniluracil, an irreversible DPD inhibitor, plus oral 5-FU (Mani et al, 2000). Only two of 55 patients (4%) treated with oral 5-FU plus eniluracil had mild HFS. These findings suggest that the degree of DPD inhibition may correlate with the frequency and grade of HFS. Although the mechanism of HFS remains unknown, it may occur secondarily to the formation of 5-FU catabolites. Owing to modulation at the DPD level, 5-FU catabolites are less likely to form during treatment with S-1 and oral 5-FU plus eniluracil, as compared with capicitabine. However, we have no direct evidence showing that FBAL causes HFS.

In conclusion, we found that oral S-1 at presently recommended doses produced a higher <i>C<sub>max</sub></i> and a greater AUC of plasma 5-FU than did PVI of 5-FU, with no elevation of the plasma FBAL concentration. During S-1 treatment, DPD inhibition by CDHP apparently resulted in lower plasma FBAL concentrations and higher plasma uracil concentrations than did PVI of 5-FU.

ACKNOWLEDGEMENTS

We thank Hideko Morita, Mari Araake, Yasuo Mizumura, Yoshihisa Tsukioka, Saori Hayashi, Chigusa Morizane, Haruyasu Murakami, and Yasuhiro Fujisaka for assistance with data collection. We also acknowledge the support of Nobutaka Samejima, Yohshiro Mizokami, Naruo Nomura, Makiko Shinogi, and Hiromi Orita, without whom we would have been unable to complete this study. This research was supported by a grant from the Ministry of Health, Labor, and Welfare, Japan.

REFERENCES

Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Ostwalder B, Griffin T (1998) Preliminary studies of a novel fluoropyrimidine carbamate: capicitabine. <i>J Clin Oncol</i> 16: 1795–1802
Chollet P, Schoffski P, Weigang-Kohler K, Schellens JHM, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC early clinical studies group (ECSG). <i>Eur J Cancer</i> 39: 1264–1270
Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989) A prospective randomized trial of leucovorin and folinic acid as a radiosensitizer. <i>J Clin Oncol</i> 8: 2116–2122
Diabio RB (1998) The role of dihydropyrimidinedehydrogenase (DPD) modulation in 5-FU pharmacology. <i>Oncology</i> 12: 23–27
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt G, Levin J, Hohneker J, Schilsky RL, Lokich J 2003 Cancer Research UK © 2003 Cancer Research UK British Journal of Cancer (2003) 89(5), 816–820

Pharmacokinetics after intravenous 5-FU and oral S-1
Y Yamada et al
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* **18**: 2894–2901

Matsushima E, Yoshida K, Kitamura R, Yoshida K (1997) Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography—negative ion chemical ionization mass spectrometry. *J Chromatogr B Biomed Sci Appl* **691**: 95–104

Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. *Br J Cancer* **83**: 141–145

Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T (1990) Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetate acid and a-fluoro-b-alanine. *Acta Neuropathol* **81**: 66–73

Peters GJ, Noordhuis P, Van Kuiilenburg ABP, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ (2003) Pharmacokinetics of S-1, an oral formulation of fluorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. *Cancer Chemother Pharmacol* **52**: 1–12

Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. *Clin Cancer Res* **4**: 941–948

Robben NC, Pippas AW, Moore JO (1993) The syndrome of 5-fluorouracil cardiotoxicity. *Cancer* **71**: 493–509

Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine antimcancer drug S-1 (1 tegafur – 0.4 sigemeast – 1 x otastat potassium) in advanced gastric cancer patients. *Eur J Cancer* **34**: 1715–1721

Sugimachi K, Maehara Y, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed S-1 fluorouracil derivative for advanced and recurrent gastrointestinal cancers. *Oncology* **57**: 202–210

Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsubakosugi S, Nakao J (1997) Phase I study of S-1. *Jpn J Cancer Chemother* **24**: 2253–2264

The Meta-Analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer. *Effect of administration schedule and prognostic factors*. *J Clin Oncol* **16**: 3537–3541

Thyss A, Milano G, Renee N, Valliicioni J, Schneider M (1986) Clinical pharmacokinetic studies of 5FU in continuous 5-day infusions for head and neck cancer. *Cancer Chemother Pharmacol* **16**: 64–66

Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. *J Clin Oncol* **18**: 1337–1345

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Shmigel WH, Seitz J-F, Thompson P, Vieitez JM, Weitzel C, Harper P for the Xeloda Colorectal Cancer Study (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol* **19**: 4097–4106

Van den Brande, Schoffski P, Schellens JHM, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, De Boer RF, Vermorken JB, Fumoleau P (2003) EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. *Br J Cancer* **88**: 648–653

Van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. *J Clin Oncol* **18**: 2772–2779

Van Kuiilenburg ABP, Stroomer AEM, Peters GJ, Van Gennip AH (2001) Simultaneous determination of F-β-alanine and β-alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography. *J Chromatogr* **759B**: 51–61

Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kosoloff M, Weichselbaum RR, Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. *J Clin Oncol* **14**: 1663–1671